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The pathogenesis of the abdominal aortic aneurysm (AAA) shows several hallmarks of 
atherosclerotic and atherothrombotic disease, but comprises an additional, predominant 
feature of proteolysis resulting in the degradation and destabilization of the aortic wall. 
This review aims to summarize the current knowledge on AAA development, involving the 
accumulation of neutrophils in the intraluminal thrombus and their central role in creating 
an oxidative and proteolytic environment. Particular focus is placed on the controversial 
role of heme oxygenase 1/carbon monoxide and nitric oxide synthase/peroxynitrite, which 
may exert both protective and damaging effects in the development of the aneurysm. 
Treatment indications as well as surgical and pharmacological options for AAA therapy 
are discussed in light of recent reports.
Keywords: aortic aneurysm, abdominal, intraluminal thrombus in aortic aneurysms, neutrophils, heme 
oxygenase-1, nitric oxide synthase
epidemiology and Risk Factors
“Aneurysm” is defined as dilatation of an artery being at least 1.5 times larger than its expected normal 
diameter (1). Thus, an abdominal aortic aneurysm (AAA) is given when the maximum diameter 
is 30 mm or more (2). Approximately, 80% of AAAs occur in the infrarenal aorta (3). In general, 
“atherosclerotic” aneurysms represent the vast majority of AAAs (Figure 1).
The prevalence of AAAs depends on patients’ age, gender, and geographical location (4). 
Primarily, elder men are affected. Men’s prevalence of AAAs below 50 mm in diameter increases 
from 1.3% below 45 years to 12.5% above 75 years (2). For women, the prevalence ranges from 
0 to 5.2%, respectively, but the risk of rupture is four times greater. The underlying mechanisms 
of sex differences are not fully understood, although women seem to be protected by female 
sex hormones (2). Smoking is another strong risk factor for the development of AAAs due to 
its promoting effects on inflammation, proteolysis, and smooth muscle cell (SMC) apoptosis 
(5). Enhanced aneurysm growth and an increased risk of rupture have been described (6). 
Other risk factors comprise previous vascular aneurysms, coronary artery and cerebrovascular 
disease, atherosclerosis, hyperlipidemia, and hypertension (4). An observational study recently 
demonstrated that a low vitamin D status was associated with the presence of larger AAAs in 
elder men (7). Moreover, various microorganisms have been associated with the pathogenesis 
of AAAs (8).
FiguRe 2 | (A) CT axial image of an infrarenal AAA with intraluminal 
thrombus. (B) Corresponding, massive, intraluminal thrombus removed 
during open surgical repair.
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In addition to these environmental components, genetic aspects 
play an important role. A positive family history for AAA especially 
in male first-degree relatives is associated with an increased risk for 
AAA (9). Moreover, alterations on chromosome 9p21 are accom-
panied with a 20% increased risk of developing AAA (10). Other 
genetic approaches suggested that aberrations of lipid metabolism 
and proteolytic pathways are the key contributors to disease. Some 
of these associations (e.g., lipoprotein receptor-related protein-1) 
are not associated with atherosclerosis, indicating pathways unique 
to AAA (11). Distinct connective tissue disorders such as Marfan 
syndrome, Ehlers–Danlos syndrome, and Loeys–Dietz syndrome 
also go along with an increased risk for AAAs (12).
The intraluminal Thrombus
In 70–80% of AAA patients, the vessel wall is covered by an intralu-
minal thrombus (ILT, Figure 2), which generally does not preclude 
blood flow and shows little compression throughout the cardiac 
cycle (13, 14). While mural thrombosis is frequently observed in 
aneurysmal disease, the complete vessel occlusion is a comparably 
rare event associated with a high rate of mortality (15).
An inhomogeneous thrombus structure was reported early on, 
with a stiffer luminal side composed of a dense fibrin network 
FiguRe 1 | cT recording of an infrarenal AAA with eccentric shape 
and sites of calcification (atherosclerotic plaques highlighted in 
white).
invaded by leukocytes and erythrocytes (16). By contrast, the 
medial and abluminal ILT layers were found to be largely devoid 
of cellular constituents and to exhibit progressive fibrinolysis and 
hence decreased thrombus strength and stiffness (17). Recent 
reports have indicated that ILT structure may indeed be more 
diverse than previously thought. When luminal, medial, and 
abluminal ILT layers were evaluated for mechanical properties, 
three subtypes of ILTs were identified (13). While the majority 
of investigated thrombi displayed a multi-layered morphology 
with gradually decreasing strength and stiffness from the distinct 
luminal to the thick medial/abluminal side (type 1), examples of 
multi-layered ILTs with an abrupt loss of mechanical resistance 
from luminal layers to rather thin and highly degraded medial/
abluminal layers were also observed (type 2). Of interest, a third 
type of single-layered ILT of almost fluid-like consistency was 
reported for a limited number of cases (13). Future studies will 
have to elucidate the pathogenesis and cellular/molecular com-
position of these distinct ILT variants. Importantly, based on the 
possibilities of medical imaging, the potential correlation of ILT 
subtype with disease progression and risk of rupture should be 
evaluated.
Macromolecular transport is promoted by centrifugal convec-
tion from the luminal to the abluminal side of the fibrin network 
and is further supported by the system of so-called “canaliculi” 
(17). Thus, molecules released and activated within the thrombus 
are readily transported to the vessel wall and affect aneurysm 
growth. Animal models have shown that limiting thrombus devel-
opment with inhibitors of platelet activation strongly suppresses 
aneurysm formation (18). The effect is accompanied by a reduction 
in leukocyte infiltration and lower release of proteases within the 
mural thrombus, which results in decreased degradation of elastic 
fibers, and promotes thrombus colonization by SMCs. Thus, by 
sequestering and activating platelets, erythrocytes, neutrophils, 
and macrophages, the ILT exposes the vessel wall to a local milieu 
of highly concentrated cytokines, proteases, and reactive oxygen 
species (ROS) that promotes aneurysm development. In line, clini-
cal studies report that ILT thickness correlates with AAA diameter, 
matrix metalloproteinase (MMP) levels, elastin degradation, and 
SMC apoptosis (19, 20). Furthermore, the presence of a large 
thrombus leads to localized hypoxia at the underlying aortic wall, 
FiguRe 3 | differential effects of heme oxygenase-1 (Hmox1) relevant 
to AAA development. Hmox1 promotes endothelial cell proliferation and 
inhibits their apoptosis, but has opposite impact on the proliferation and 
apoptosis of smooth muscle cells. It can also modulate thrombus formation 
by inhibition of platelet aggregation and promotion of fibrinolysis. cGMP, 
cyclic guanosine monophosphate; PAI-1, plasminogen activator inhibitor-1; 
SMC, smooth muscle cell.
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which triggers adventitial angiogenesis and aggravates inflamma-
tory infiltration from the outer vessel layers (21).
Despite this role in supporting the inflammatory and proteo-
lytic mechanisms of AAA pathogenesis, the mural thrombus has 
repeatedly been suggested to protect the aneurysm from rupture by 
reducing the peak wall stress and altering wall stress distribution 
(22). However, this protective role seems to depend on the degree 
of thrombus attachment to the vessel wall (23). When bearing 
in mind that large thrombi are reportedly associated with faster 
AAA growth, the proteolytic weakening of the AAA wall may be 
the more predominant ILT effect when compared to wall stress 
relief (24).
Proteomics analysis of proteins sequestered by the ILT fibrin 
network revealed the expected prevalence of platelet-derived 
proteins such as clusterin and thrombospondin-1 (25), which are 
likely to be subjected to proteolytic processing within the local 
thrombus milieu thereby altering or activating protein function 
(26). Furthermore, as the ILT constitutes a site of continuous 
hemostasis and fibrin destruction, the respective coagulation and 
fibrinolysis factors are detected in thrombus tissue and elevated 
in AAA patients’ blood (27). Fibrinogen, D-dimer (a cross-linked 
fibrin degradation product) and TAT (thrombin–antithrombin 
complex) prevailed in meta-analysis as diagnostic markers (28). 
Furthermore, circulating concentrations of hemostatic and fibrino-
lytic markers correlated with AAA and ILT size (29) and D-dimer 
blood levels were suited to predict the AAA growth rate (30). 
Importantly, large, population-based health screenings identified 
elevated blood levels of fibrinogen and tissue plasminogen activa-
tor to be associated with the occurrence of AAA within the sub-
sequent 10–20 years follow-up period. The fact that these plasma 
proteins were elevated years before the clinical manifestation of 
disease further supports the notion that deregulated hemostasis/
fibrinolysis is intricately involved in AAA pathogenesis – starting 
at an early stage of disease (31).
The factors potentially protecting or predisposing an individual 
to AAA development have been subjected to intense investigation. 
Loss of endothelial homeostasis resulting in pro-inflammatory 
and pro-coagulant activation is proposed to trigger the onset of 
disease. Two molecules that are central in regulating endothelial 
homeostasis and may thus exert a protective function are carbon 
monoxide (CO) and nitric oxide (NO) (32, 33). However, a more 
complex picture has emerged with CO, NO, and their enzymatic 
or reactive by-products exhibiting additional effects on, e.g., SMC 
proliferation and survival, which may promote rather than inhibit 
AAA development (34, 35). The loss of SMCs is a hallmark of the 
weakening vessel wall. In addition, AAA pathogenesis involves the 
destruction of elastic fibers and other matrix components, which 
seems to be vitally regulated by the accumulation of neutrophils 
in the growing ILT (36). These central mechanisms of disease 
development are highlighted in the following review sections.
Role of Heme Oxygenase 1 in AAA and iLT
Heme oxygenase-1 (Hmox1) and products of its activity can affect 
blood coagulation and formation of the thrombus. Hmox1 is an 
enzyme degrading heme – as released by erythrocyte trapping and 
hemagglutination in the thrombus – to carbon monoxide (CO), 
ferrous iron (Fe2+), and biliverdin, which is subsequently reduced 
by biliverdin reductase to bilirubin. Hmox1 has anti-oxidant, anti-
inflammatory, and cytoprotective activity that is crucial for blood 
vessel homeostasis (32) (Figure 3). Carbon monoxide activates 
guanylate cyclase, increases the level of cGMP (cyclic guanosine 
monophosphate), and subsequently inhibits platelet aggregation 
(37). Moreover, CO has been shown to suppress plasminogen 
activator inhibitor-1 (PAI-1) in a lung ischemia-driven thrombosis 
model (38) and subsequently affects fibrinolysis. Accordingly, 
both CO and bilirubin suppress PAI-1 in Hmox1-deficient mouse 
embryonic cells (39).
The majority of studies characterizing the role of Hmox1 in 
hemostasis and thrombosis have been performed on the occlusive 
types of thrombosis as opposed to AAA. Lack of heme oxygenase-1 
in Hmox1−/− mice leads to the faster occurrence of an occlusive 
thrombus in the carotid artery after photochemical injury (40). 
Basal levels of carotid tissue factor, platelet counts, bleeding 
time, and prothrombin time were not different in Hmox1+/+ and 
Hmox1−/− mice. However, vascular injury induced higher levels 
of arterial tissue factor and von Willebrand factor in Hmox1−/− 
than in Hmox1+/+ mice. Also, photochemical injury led to the 
endothelial damage only in Hmox1−/− mice. Finally, Hmox1+/+ mice 
transplanted with Hmox1−/− bone marrow showed accelerated 
thrombosis in comparison to the Hmox1+/+ mice that received 
Hmox1+/+ bone marrow. Interestingly, faster occlusive thrombus 
formation in Hmox1−/− mice could be rescued with biliverdin, or 
when mice were inhaled with sublethal doses of CO (40).
Similarly, in the model of stasis-induced thrombosis in the 
inferior vena cava (IVC), the clot was bigger in Hmox1−/− mice 
(41). IVC ligation increased Hmox1 transcription and protein 
levels in wild type endothelial and SMCs as well as in infiltrating 
FiguRe 4 | schematic diagram showing the generation of nO and 
OnOO− from a coupled enOs and an uncoupled enOs in a normal 
and a dysfunctional endothelium, respectively. eNOS, endothelial nitric 
oxide synthase; NAD(P)H, nicotinamide adenine dinucleotide (phosphate); 
TDB, tetrahydrobiopterin.
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cells. It was demonstrated that IVC ligation in Hmox1−/− mice 
induced a higher activation of nuclear factor kappa B (NF-κB) 
transcription factor and increased the inflammatory response 
as reflected by the expression of interleukin-6 (IL-6), monocyte 
chemoattracting protein-1 (MCP-1), stromal cell-derived factor-1, 
and KC (the murine homolog of interleukin-8) than in wild type 
animals. Importantly, the activity and expression of MMP-9 were 
also elevated in Hmox1−/− mice. Finally, similar to the model of 
carotid artery injury in the work by True et  al. (40), the vena 
cava ligation led to the increased production of tissue factor in 
Hmox1−/− mice (41).
Cobalt protoporphyrin IX (CoPP), a known inducer of heme 
oxygenase-1, inhibits formation of the thrombus in response to 
laser ablation of endothelium in cremaster arterioles, whereas tin 
protoporphyrin IX (SnPP), a heme oxygenase-1 inhibitor, leads 
to enhanced thrombus formation (42). Interestingly, in a murine 
model of aorta allotransplantation, the thrombus was formed 
when aortas from Hmox1−/− were grafted (43). The effect of the 
lack of Hmox1 was rescued with carbon monoxide releasing 
molecule-2 (CORM-2) (43). Moreover, administration of hemin, 
which not only induces Hmox1 but also promotes oxidative stress, 
resulted in faster clot formation in response to ferric chloride in 
Hmox1−/− mice than in Hmox1+/+ mice, which was not observed 
under basal conditions (44). Noteworthy, in animals with a normal 
level of  Hmox1 hemin may have a protective activity. Prophylactic 
treatment of Wistar rats with hemin reduced carotid thrombus 
formation in response to the electric stimulation (45). A similar 
observation was found in the mouse cremaster microvascular 
circulation, where hemin delayed formation of the thrombus in 
response to ferric chloride (46).
Despite the fact that the majority of functional studies regarding 
the role of Hmox1 in thrombus formation were conducted in the 
context of occlusive thrombosis, there are several findings that 
implicate Hmox1 in AAA pathobiology. Of note, expression of 
Hmox1 is increased in rat aorta on days 7 and 10 after AAA induc-
tion with elastase (47). Enhanced expression of Hmox1 prevents 
endothelial cell apoptosis and facilitates endothelial proliferation 
(32). By contrast, upregulation of Hmox1 in vascular SMCs 
induces p53 expression and promotes apoptosis (48). Noteworthy, 
increased SMC death and a high level of p53 is a common feature 
of AAA lesions and the weakening vessel wall (49). Furthermore, 
carbon monoxide inhibits the rat aortic SMC proliferation under 
hypoxic conditions in response to endothelin-1 (34). Moreover, 
probucol, which is used to prevent restenosis, increases Hmox1 
levels in SMCs and therefore inhibits their proliferation (50). The 
diverse effects that Hmox1 and its enzymatic products may exert 
in the AAA setting (such as reducing thrombus formation, yet 
increasing SMC apoptosis) are summarized in Figure 3.
Importantly, the level of Hmox1 expression in humans is modu-
lated with the microsatellite polymorphism of the gene promoter 
(51). Namely, a longer promoter with more guanidine–thymidine 
(GT) repeats (n ≥ 29) results in lower basal expression of Hmox1 
and weaker upregulation in response to stimuli (52). It was shown 
that human umbilical vein endothelial cells with a short Hmox1 
promoter (n ≤ 23) survive better under oxidative stress, proliferate 
more effectively in response to vascular endothelial growth fac-
tor and produce less pro-inflammatory cytokines such as IL-1β, 
IL-6, and soluble intercellular adhesion molecule-1 (52). The 
frequency of carriers of the short GT repeat allele of the Hmox1 
promoter was significantly lower in Austrian AAA patients than 
in coronary or peripheral artery disease-matched controls (53). 
Similarly, there was a higher frequency of the longer GT repeat 
allele of the Hmox1 promoter in patients with cerebral aneurysms 
(54). This may suggest that a higher expression or inducibility 
of Hmox1 may play a protective role against AAA development. 
By contrast, in a group of Croatian AAA patients, there was a 
higher frequency of the carriers of short GT repeats in the Hmox1 
promoter than in the non-AAA group (55). Thus, the relation 
between AAA development and Hmox1 promoter polymorphism 
requires further analysis.
Role of nO and nitroxidative stress in 
Aortic Aneurysm Formation
Nitric oxide (NO) can be produced by three nitric oxide synthases 
(NOS): endothelial – eNOS, neuronal – nNOS and inducible – 
iNOS. In endothelium, NO is produced mainly by eNOS (Figure 4). 
Its release depends on the velocity of blood flow and the diameter of 
the vessel. In the cardiovascular system, NO regulates the blood flow 
as well as prevents platelet and leukocyte adhesion and aggregation 
(33, 56, 57). Under laminar flow, there is a homogeneous thin 
layer (about 1–3 μm) of NO in close proximity to the arterial wall. 
However, under turbulent or semi-turbulent flow, the NO layer can 
be depleted (58). Therefore, NO production from the endothelium 
under turbulent flow is significantly higher than under laminar 
flow. Under this turbulent flow and under intensive production 
of NO, eNOS can become uncoupled, which leads to dysfunction 
of the endothelial cells (58, 59). This process is observed in many 
cardiovascular diseases including atherosclerosis, hypertension, 
stroke, diabetes, and aneurysm. The uncoupling of eNOS can be 
attributed to a shortage of substrates of eNOS (L-arginine and/
or oxygen) as well as cofactors of eNOS like tetrahydrobiopterin 
(THB) (60, 61). Uncoupled eNOS can concomitantly generate NO 
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and superoxide ( )O2
- . NO can react rapidly in a diffusion controlled 
reaction with O2
- to produce peroxynitrite (ONOO−). Peroxynitrite 
is a short lived (t1/2 < 1 s) molecule with an oxidation power that is 
much higher than that of NO or O2
-. Therefore, high concentrations 
of ONOO− can cause significant damage to proteins, enzymes, and 
DNA in a biological milieu (62, 63).
The role of NO in the development of aneurysm is ambiguous 
and unclear. There are several studies concerning eNOS- and iNOS-
derived NO in the pathology of aneurysms performed on animal 
models and human beings (64–68). However, the results produced 
by these studies are very often contradictory. Aneurysmal degen-
eration is a result of biochemical and biomechanical processes, 
which finally lead to the partial destruction of the aortic wall (49). 
Nitric oxide and peroxynitrite may be involved in many of these 
processes. The effect of turbulent flow will be more pronounced with 
the increase in diameter and asymmetry of aneurysms (69). Based 
on our studies, the change of flow from laminar to turbulent would 
lead to a higher level of NO concentrations and a higher expression 
of eNOS (62, 63). However, an increase in eNOS expression does 
not always produce a higher level of bioavailable NO (diffusible 
NO, which can be involved in cellular signaling), because it is not 
usually accompanied by an increase in the levels of L-arginine 
or cofactors like THB. At an insufficient level of substrates and 
cofactors, the dimeric form of eNOS enzyme can be uncoupled 
and the net effect of uncoupled eNOS correlates inversely with the 
level of bioavailable NO and directly with ONOO− concentrations. 
Thus, while NO production by eNOS is known to play a protective 
role in the cardiovascular system by its vasodilatory effect, Gao 
et al. found that eNOS uncoupling/THB deficiency accelerated the 
formation of AAA in mice (64). Comparably, it has been suggested 
that eNOS deficiency increased in atherosclerosis in Western-type 
diet-food apoE knock-out mice and triggered spontaneous aortic 
aneurysms (66). Furthermore, NO may play a role in the MMP 
regulation in AAA: NO produced via eNOS inhibits MMP activity 
and inhibits SMC migration (65, 68).
Animal models demonstrated that inhibition of iNOS decreased 
NO generation and inhibited aneurysm formation. However, the 
opposite effect was also reported. Lee et al. demonstrated in animal 
models that iNOS does not play a requisite role in the process of 
elastase-induced experimental aneurysmal degeneration in mice 
(67). The authors also suggested that therapeutic treatment of 
aneurysms by inhibition of iNOS may have a deleterious effect. 
Most published studies on models of aneurysm indicate that iNOS 
expression increases while eNOS decreases during aneurysmal 
degeneration.
We believe that a likely reason for these confusing results is due 
to the heterogeneous distribution of NOS along the wall of an aneu-
rysm. In our opinion, the type of flow (laminar versus turbulent) 
could be a determining factor, which will influence the kinetics of 
NO release, expression of eNOS and iNOS, and NO bioavailability 
in different segments of aneurysmal tissue. Therefore, one can 
assume that it is highly unlikely that a lateral NO distribution in the 
aneurysm will be homogeneous, but it will not be. Thus, analysis 
of a sample of aneurysm without information providing specific 
locations (coordinates) of the aneurysmal tissue may be flawed. An 
indication of NO production by iNOS has been closely associated 
with inflammation, which follows an increase in the dysfunction 
of the endothelium, the increase in eNOS uncoupling, and an 
increase in peroxynitrite and nitroxidative stress. It is well accepted 
that ONOO− is directly involved in the triggering of inflammation. 
Endothelial, bioavailable NO is cytoprotective, while peroxynitrite 
is cytotoxic. The balance between the concentrations of these two 
molecules has to be measured along the arterial wall at well-defined 
coordinates. These kinds of measurements have never been done 
and this is likely the reason for the very conflicting picture seen 
for the role of NO in the development of aneurysms. Recently, 
our laboratory developed a system of nanosensors (diameter of 
lower than 300 nm), which can be placed near the endothelium 
of an aortic aneurysm for the simultaneous, in situ measurements 
of NO, ONOO−, and O2
- (62, 63). The preliminary data obtained 
from these experiments indicate a substantial difference in the 
kinetics and concentration of the release of NO, as well as the 
release of the other components of nitroxidative stress at different 
segments of aneurysms. NO plays a significant role in the early 
events in aneurysm formation and this mechanism may not be 
related to hypertension. During this early event, uncoupled eNOS 
starts to produce significant concentrations of ONOO−, changing 
the balance between the cytoprotective NO and the cytotoxic 
ONOO− (70). The NO/ONOO− imbalance stimulates iNOS, which 
starts to produce uncontrollably high levels of NO, as a protec-
tive measure. However, this increase in NO production by iNOS 
causes further uncoupling of eNOS due to local consumption of 
L-arginine. The net effect of these processes (nitroxidative stress) 
stimulates a cascade of events, which lead to the elevated genera-
tion of additional oxidative and nitroxidative species, including 
O2
-, ONOO−, and H2O2. The stimulation of NAD(P)H, under this 
condition, contributes to the elevation of O2
-, oxidation of THB, 
and the further enhancement of ONOO− levels (62, 64).
Therefore, the low level of bioavailable NO and the high level of 
nitroxidative and oxidative stress can be considered as important 
factors in the initial stage of aneurysm development. This process 
can be similar to that observed in atherosclerosis. Nitroxidative 
stress can trigger several processes leading to the injuring of 
endothelial cells and SMCs, upregulation of chemotactic cytokines, 
upregulation of NAD(P)H and adhesion molecules, as well as 
activation of MMPs (71). All of these processes can contribute to 
vessel wall remodeling and breakdown. As the aneurysm devel-
ops further, NO is involved in the inhibition of smooth muscle 
proliferation, nitroxidative stress, and the change of angiogenic 
activities (35, 72). This may result in the serious destruction of 
extracellular matrix and elastic fibers. The net effect of NO and 
ONOO− action can be the thickening and weakening of the arte-
rial wall and finally its rupture. We believe that the ratio of NO 
concentration to ONOO− concentration and non-homogenous 
distribution of oxidative/nitroxidative stress plays a crucial role 
in the development of the aneurysm.
Role of neutrophils in Aortic Aneurysm 
Formation
The bulk amount of ROS and reactive nitrogen species (RNS) in 
AAA and ILT is produced by activated polymorphonuclear cells 
like neutrophils. Neutrophils have pro-oxidant activities via, e.g., 
NADPH oxidase and myeloperoxidase. Myeloperoxidase is a 
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heme enzyme, which is expressed in 95% of polymorphonuclear 
neutrophils (PMNs). Both myeloperoxidase and NAPDH oxidase 
are primarily involved in the generation of ROS/RNS (73). Ramos-
Mozo et  al. showed a decreased catalase activity in circulating 
PMNs as well as in plasma from AAA patients, indicating that 
neutrophils of AAA patients have a reduction in anti-oxidant 
enzymes (74). By contrast, H2O2 levels and MPO levels in isolated 
PMNs were significantly higher than in controls. Therefore, a redox 
imbalance toward increased oxidative stress in AAA patients could 
be a key factor in AAA formation (74). However, PMNs do not only 
contribute to oxidative stress but also to proteolytic degradation of 
the aortic media and to adventitial inflammation (75). Importantly, 
PMN depletion showed a significant inhibition of experimental 
AAA formation thus pointing to the central role of neutrophils in 
AAA pathogenesis (76).
The luminal layer of the ILT is the predominant site of leuko-
cyte retention. In the luminal ILT IL-8, a neutrophil chemotactic 
factor is released four times higher than in the AAA wall (77). 
Leukotriene B4 (LTB4) is another potent leukocyte chemoat-
tractant and mediator of inflammation. Houard et  al. showed 
thrombus-derived LTB4 as a mediator of neutrophil chemotaxis 
(78). Again, the luminal layer of the ILT had the highest activity. 
Furthermore, the alternative complement pathway was found to be 
activated in the AAA setting (79) and C5a had the specific ability to 
chemoattract neutrophils and trigger oxidative burst by inducing 
the release of CXC chemokines (80). Pagano et al. showed in a 
murine model that elastase-induced AAA is indeed complement 
(C3a, C5a) dependent (79). Neutrophils are 12 times more numer-
ous in clots than in blood because these cells have a high affinity 
for the fibrin–fibronectin network. They bind to fibrin via integrins 
and to platelet-exposed P-selectin via the expression of the sialyl 
Lewis-X-containing polysaccharide ligand (81). Neutrophils are 
terminally differentiated cells, which undergo constitutive apopto-
sis after binding; this process is postponed upon NF-κB activation 
in neutrophils (82) as facilitated in the context of the ILT.
The presence of an ILT has been associated with a thinner 
arterial wall (21), more extensive elastolysis, a lower density of 
SMCs in the media, and a higher level of immuno-inflammation 
in the adventitia (19). This suggests that an important part of 
the protease activity originates from the ILT in contrast to the 
previously suspected direct generation within the AAA wall. 
The ILT is particularly rich in pro- and active forms of MMP-9 
(83), and MMP-9–lipocalin complexes, which are of neutrophil 
origin (84). Localization of neutrophils in the luminal part of the 
thrombus is associated with increased levels of MMP-8, MMP-9, 
and elastase compared with other (medial and abluminal) layers 
of the ILT (36). Neutrophils release granular serine proteases such 
as urokinase plasminogen activator, elastase, proteinase 3, and 
cathepsins from their azurophilic granules. MMP-9 and MMP-8 
are released from gelatinase granules. The cysteine proteases are 
also potent elastolytic and collagenolytic enzymes associated 
with AAA development. Several cathepsins (85) and dipeptidyl 
peptidase I (86) have been reported to be elevated in AAA tissue, 
combined with a decrease in their cystatin inhibitors. Dipeptidyl 
peptidase I is a lysosomal cysteine protease, which is of central 
importance, as it promotes the activation of granule-associated 
serine proteases, including neutrophil elastase, cathepsin G, and 
proteinase 3 (87). Neutrophil proteases may essentially degrade all 
types of matrix fibrillar proteins and thus promote AAA progres-
sion and ultimate wall rupture. The site of final adventitial rupture 
is characterized by a high level of protease expression (88) and a 
prominent enrichment of leukocytes and focal neovascularization 
(89). Of interest, Lindholt et al. have reported a protective effect of 
calcification in the evolution of AAA, probably explained by the 
greater resistance of calcified tissue to proteolysis (90).
Abdominal aortic aneurysm biomarkers are of great scientific 
interest, as a specific biomarker for prediction of AAA rupture is 
urgently needed. There are no AAA-specific laboratory markers; 
however, neutrophil-related factors may have future prospects. 
Ramos-Mozo et  al. showed that plasma levels of neutrophil 
gelatinase-associated lipocalin are increased in AAA patients and 
correlate with AAA growth, reflecting the potential activation of 
both resident and circulating neutrophils (91). Despite the fact that 
AAA-related biomarkers have the limitation of not being disease 
specific due to a strong connection to general atherosclerosis, 
MMP-9 levels were found to have a significant correlation with 
AAA diagnosis (92). In addition to the marker potential, neutro-
phils (and PMN-related factors) constitute a therapeutic target 
in AAA patients. Doxycycline can directly inhibit MMP activity, 
and it effectively suppresses the development of elastase-induced 
AAAs in preclinical models (93). In clinical trials, preoperative 
doxycycline therapy improved the proteolytic balance in human 
AAA by reducing aortic wall neutrophil content (94). Doxycycline 
treatment resulted in a 2.5-fold decrease of MMP-9 protein levels 
(95). Lindeman et al. could show a strongly reduced PMN and 
cytotoxic T-cell content of the aortic wall after a 2-week doxycy-
cline treatment of AAA patients indicating that the doxycycline-
mediated effects are not restricted to neutrophils (96).
Treatment indications
Biodegradation of the abdominal aortic wall determines aneurys-
mal growth. Average growth rates of AAAs below 55 mm in size 
range from 2 to 3 mm per year. Larger AAAs are associated with 
higher growth rates (4). Most AAAs are asymptomatic, and the vast 
majority is detected occasionally during routine investigations. 
Risk factors for progression to rupture comprise hypertension, age, 
female sex, and persistent smoking (4). Finally, the life-threatening 
risk of rupture has to offset the operative mortality for aneurysm 
repair. For small fusiform AAAs (AAA diameter 30–39  mm), 
the 12 months risk of rupture is 0%, and it is still about 1% in 
those cases when the AAA diameter ranges between 40–49 mm 
(4). As a consequence, several studies recommended pursuing a 
surveillance policy in these cases (97). However, the 12 months risk 
of rupture rises exponentially with further increase of the aortal 
maximum diameter. Consequently, the threshold for aortic repair 
is 50 mm for women and 55 mm for men (4).
Besides the diameter of the AAA, its morphology plays another 
important role in the decision for repair. Fusiform AAAs are 
thought to be less prone to rupture than saccular AAAs, or those 
with eccentric components (Figure 1). Peak wall stress, presence 
of an ILT (Figure 2), and AAA wall mechanics are the factors 
most implicated with rupture risk. Therefore, early repair has been 
advised in these cases (98).
FiguRe 5 | (A) Successful exclusion of an infrarenal AAA by a tube graft. 
Iliac bifurcation intact. (B) Successful exclusion of an infrarenal AAA by a 
bifurcated stent graft.
FiguRe 6 | (A) Invasive angiography prior to endovascular repair (EVAR): 
rupture of an infrarenal AAA. (B) Final angiography after EVAR: successful 
exclusion of the ruptured AAA by a bifurcated stent graft; no endoleak visible.
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Symptomatic AAA is characterized by abdominal, back, or 
chest pain (99). Peripheral embolization with subsequent ischemia 
may be another sequel of AAAs with intraluminal thrombus (4). 
Peak wall stress is significantly greater in symptomatic or ruptured 
AAAs compared to asymptomatic AAAs according to a recent 
meta-analysis (98). As a consequence, early repair has been recom-
mended in symptomatic patients (4, 98). Likewise, rapid aneurysm 
growth with more than 10 mm per year represents another indica-
tion for early repair (4). In conclusion, these recommendations aim 
to prevent AAA rupture, a life-threatening event with mortality 
rates of approximately 65–85% (100).
surgical Repair
Thorough preoperative evaluation of the patient’s comorbid 
diseases is a prerequisite for any type of surgical repair as its 
outcome essentially determines the decision between open or 
endovascular repair. Second, optimization of the treatment for 
various comorbidities should be obtained (4). Moreover, computed 
tomography (CT) or magnetic resonance angiograms are necessary 
to outline the morphological characteristics of AAAs for devising 
the operative strategies in open surgical repair (OSR) as well as 
for selection of the appropriate stent graft for endovascular aortic 
repair (EVAR). OSR is the mainstay in elective AAA cases. In 
general, tube grafts (Figure 5A) are preferred to bifurcated grafts, 
due to reduced dissection with less risk of injury to adjacent 
structures and consecutively shorter operating time (4). In case 
of additional iliac artery aneurysms or concomitant iliac arte-
rial occlusive disease, indication for a bifurcated graft is given 
(Figure 5B). Since the introduction of EVAR via a transfemoral 
approach by Volodos in 1984 (101), this technique has become of 
wide-spread use (Figure 6).
An advantage of EVAR over OSR is less surgical trauma. 
Moreover, general anesthesia can be avoided. EVAR, however, 
requires adequate aortic and iliac fixation sites for effective seal-
ing and fixation (4). Tortuous iliac arteries or extreme kinking of 
the aorta may prevent from adequate insertion or fixation of the 
stent graft in up to 40% of the patients. Endoleak after EVAR is 
a common complication in up to 25% of patients (4). In general, 
AAA patients suffer from a pro-thrombotic tendency. While the 
incidence of AAA-related disseminated intravascular coagulation 
(DIC) prior to surgery is rare and may be resolved upon AAA 
repair, the occurrence of DIC as a perioperative coagulopathy is 
a more frequent complication (102). In addition, a high incidence 
of venous thrombosis is observed after elective AAA repair despite 
systematic heparin application (103) and both coagulopathy as well 
as a hyperfibrinolysis are similarly encountered in ruptured AAA 
repair (104). It has been subject of investigation whether the two 
types of surgical intervention (OSR versus EVAR) differ in their 
hemostasis effects (27). Both were found to further aggravate the 
pro-coagulant and hyperfibrinolytic state of AAA patients in the 
initial post-operative period (105, 106) while reducing the circulat-
ing markers of deregulated hemostasis/fibrinolysis several months 
after AAA repair (107). Despite the fact that EVAR represents a 
smaller surgical trauma, a number of studies observed that EVAR 
as compared to open surgery led to higher marker levels in the 
immediate perioperative phase as well as the long-term period 
(108). This indicates that the inherent procedure and materials 
of EVAR may extend the hemostatic imbalance after AAA repair.
With respect to overall outcome, meta-analyses of prospective, 
randomized, controlled trials showed that 30-day mortality was 
higher in OSR (3.2–4.2%) versus EVAR (1.2–1.4%) in elective 
AAAs (109–111). However, there were no differences in the 
long-term (>4 years) all-cause mortality between EVAR (37.3%) 
and OSR (37.8%) (109, 110, 112). Causes of deaths were primarily 
cardiovascular events with similar incidences of cardiac death and 
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fatal stroke, and malignant diseases (109, 112). Moreover, there 
were no significant differences in aneurysm-related mortality. 
Re-intervention rates, however, were significantly higher and more 
aortic related after EVAR (18.9%) compared to OSR (9.3%) (110).
The incidence of ruptured AAAs ranges between 6 and 18 
per 100 000 person-years in Western countries (4). The overall 
mortality rate is extremely high with up to 80–90%. AAA rupture, 
defined as bleeding outside the adventitia of the dilated aortic 
wall, is classified into free rupture into the peritoneal cavity with 
extremely poor outcome or retroperitoneal rupture. Treatment 
strategies are of importance in aortic surgery, as clamping of the 
aorta is connected with a massive lower torso ischemia. Pre- (113) 
and post-conditioning (114) should activate the endogenous 
anti-oxidant defense mechanisms. Additionally, early infusion of 
radical scavengers plus L-arginine and cofactors (59, 61, 115, 116) 
play an important role to ameliorate deleterious consequences. 
Following these strategies, a reduction of 30-day mortality rates 
(52%) was noticed (117). In our own studies, the 90-day mortality 
rate for patients receiving OSR was 29% (118). In the last decade, 
a progressive increase in the proportion of patients managed by 
EVAR in case of ruptured AAAs was observed. Importantly, it has 
been shown that successful exclusion of ruptured AAAs by EVAR is 
feasible. Several studies showed significantly lower 30-day mortal-
ity rates after EVAR (24%) compared to OSR (52%) (111, 117). 
The survival advantage for EVAR after ruptured AAA persisted 
during the first 5 years after repair, but was lost after that period. 
The estimated 5-year survival was 44 and 39% for EVAR and OSR, 
respectively (117). By contrast, a recent meta-analysis including 
only randomized controlled trials failed to show superior outcome 
after EVAR compared to OSR (119). Moreover, long-term data are 
lacking for both survival and complications (119).
In conclusion, evaluation of the literature on OSR versus EVAR 
in both elective and ruptured AAAs failed to show superiority 
of one of these treatments in the long run, because randomized 
controlled trials do not consider the various risk factors, which 
account for the final outcome. Therefore, the tailored approach 
attributing geriatric patients with multiple morbidities to EVAR 
resulted in better outcome rates – at least initially (120, 121). In 
individuals considered unfit for OSR, no difference between EVAR 
and the non-intervention group with regard to all-cause mortality 
(21% in each group), with higher aneurysm-related deaths in the 
non-intervention group have been described (109). This finding 
may prompt us to avoid excessive surgery in geriatric and high-risk 
patients with multiple comorbidities. Future research, however, 
should aim at predictors for AAA growth and rupture. New 
biochemical markers along with functional imaging may help to 
select patients who are at risk at an early stage.
Pharmacological Treatment Options
Based on the outlined pathomechanism of disease, various 
pharmacological treatments are offered to AAA patients in addi-
tion to surgical intervention, which is limited to the progressed 
state (Figure 7). According to the European Society for Vascular 
Surgery guidelines for the management of AAA, statins and 
anti-platelet drugs should be used in patients diagnosed with 
AAA (4). Statins should be started 1 month before intervention 
to reduce cardiovascular morbidity and should be continued in 
the perioperative period for an indefinite duration; while aspirin 
at low doses should be prescribed on diagnosis and continued 
through the perioperative period unless a contradiction exists (4). 
However, only statins were indicated to both reduce cardiovascular 
mortality in AAA patients and to slow the rate of AAA growth. On 
the contrary, among the drugs that do not affect AAA growth but 
may be indicated for comorbidities are beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors, and AT1-receptor antago-
nists (122).
Abdominal aortic aneurysm is thought to be an inflammatory 
disease as patients with AAA exhibit increased values of inflamma-
tory parameters such as C-reactive protein (123), or cytokines like 
tumor necrosis factor alpha (TNF-α) (77). Indeed, AAA and ILT 
are sources of physiologically active cells, including macrophages, 
T-cells, B-cells, and neutrophils that produce large amounts of 
messenger molecules (124). SMCs and endothelial cells in the AAA 
wall as well as red blood cells and platelets in the intraluminal 
thrombus are a source of free oxygen and nitrogen radicals. 
When activated platelets produce intracellular superoxide anion 
via NADPH oxidase, it conversely increases platelet recruitment 
favoring thrombus formation (125).
statins
The guidelines are based on experimental and clinical evidence 
of the positive effect of statins in AAA prevention and treatment. 
It was reported that statins may prevent aneurysm formation 
in animal models (126). Moreover, some observational studies 
in humans presented a 50% reduction in AAA expansion rate 
(127), and an association between statin therapy and a risk of 
AAA rupture (6). Also, a randomized trial reported that fluvastatin 
(80 mg daily for 30 days before surgery and continued until at least 
30 days after surgery) halved both the primary 30-day outcome of 
post-operative myocardial ischemia and the secondary outcome 
of non-fatal myocardial infarction and cardiovascular death (128). 
A recent large meta-analysis showed that statins reduce the rate of 
progression of AAA (129). The meta-analysis by Galinanes et al. 
(130) reported that 1  week of statins administered to patients 
undergoing OSR or EVAR was associated with improved survival 
during 1 year after surgery and a decreased incidence of lower 
extremity embolic complications after EVAR.
In our previous report, we showed that simvastatin decreased 
the rate of free radical formation and the content of pro-inflamma-
tory molecules like TNF-α in the aneurysmal wall (131). Therefore, 
protection of the AAA wall from ROS may be an important factor 
in the reduced AAA rupture risk. Furthermore, patients with a 
higher baseline C-reactive protein level respond better to statin 
therapy and have a lower absolute vascular risk than those without 
statins, as the findings of the JUPITER trial documented (132). 
The anti-inflammatory effect of statins may be in part connected 
with their influence on pro-inflammatory signaling pathways. 
Simvastatin taken for at least 6 months decreased the activity of 
NF-κB and ERK1/2 signaling pathways in the aortic wall of AAA 
patients (131, 133). A reduction in NF-κB activity under statins 
may be in part related with modulation of NF-κB in infiltrating 
T helper cells and CD40 signaling in SMCs and mononuclear 
cells (134), resulting in lower synthesis and release of IL-6 and 
FiguRe 7 | Molecular changes in the aneurysmal wall, which may be 
targeted by pharmacological treatment. Compounds generated in the 
extracellular matrix (ECM) like free oxygen or nitrogen species (ROS/RNS), 
inflammatory cytokines, e.g., tumor necrosis factor alpha (TNF-α) or cyclophilin 
A, and angiotensin II (through angiotensin receptor 1; AT1) stimulate 
inflammatory cells like macrophages or neutrophils, and platelets inside the 
AAA wall. Next, macrophages/neutrophils act on T and B lymphocytes 
initiating humoral and cell-mediated immune responses and leading to 
inflammation. As a consequence, pro-inflammatory signaling pathways 
involving NF-κB, T-bet, STAT-4, STAT-6, or GATA-3 are activated and a large 
amount of pro-inflammatory cytokines is released. Moreover, activated 
leukocytes produce matrix metalloproteinases (MMPs), which degrade elastic 
fibers inside the AAA wall. The activation of AT1 receptor and increased 
production of ROS/RNS by leukocytes activate platelets that form the 
intraluminal thrombus. Those changes, however, may be slowed down or 
eliminated by statins, anti-platelet drugs, or ACE inhibitors. ACE inhibitors, 
angiotensin-converting-enzyme inhibitors; Ang II, angiotensin II; AT1, 
angiotensin II receptor type 1; GATA, trans-acting T cell-specific transcription 
factor; MMP, matrix metalloproteinase; ROS, reactive oxygen species; RNS, 
reactive nitrogen species; STAT, signal transducer and activator of 
transcription; TGF-β, transforming growth factor beta; Th, T helper cell; TNF-α, 
tumor necrosis factor alpha.
May 2015 | Volume 2 | Article 199
Piechota-Polanczyk et al. AAA and ILT: current concepts
Frontiers in Cardiovascular Medicine | www.frontiersin.org
IL-8 (135). Recently, van de Meij et al. (124) confirmed previous 
findings that patients who underwent AAA repair treated with 
simvastatin and atorvastatin at clinical doses had a reduced tissue 
content of macrophage-related markers and NF-κB dependent 
inflammatory molecules such as IL-6 and MCP-1, however, 
without a decrease in macrophage content.
Furthermore, inflammatory mediators regulate the expression 
and activity of MMPs released mainly by activated neutrophils 
and macrophages. In animal models, statin therapy suppressed the 
extent of AAA formation by 25%, and the incidence of AAA by 30% 
(136). The effect was associated with a reduction in MMP-9 protein 
and gene expression. In clinical trials, simvastatin was found to 
significantly lower MMP-9 concentrations by 40% within the 
aneurysm wall compared to placebo (137). Importantly, MMPs are 
inhibited when complexed with tissue inhibitors of MMPs (TIMPs). 
It was reported that MMP-9 and TIMP-1 as well as MMP-2 and 
TIMP-2 correlate with ILT thickness in patients with AAA (20). 
Therefore, statins may have beneficial effects to slow AAA growth.
Anti-Platelet Therapy
Meta-analyses of randomized trials on primary and secondary 
prevention of AAA with anti-platelet therapy suggested that all 
patients diagnosed with AAA should be started on aspirin therapy 
at the time of AAA diagnosis as the use of low-dose aspirin may 
be associated with a reduction in all vascular deaths (138). Recent 
epidemiologic data indicate that the initiation of lifelong aspirin 
therapy should be considered as soon as a diagnosis of AAA is 
made (139). However, a retrospective study, which investigated 
aortic aneurysm cases between 1999 and 2006 from the National 
Health Insurance Research Database found no association between 
low-dose aspirin exposure and mortality or exacerbation in dif-
ferent types of aortic aneurysms (140).
Animal studies also showed that aspirin may significantly 
reduce both aortic plaque size and thrombus formation after vessel 
injury (141). Those effects may be in part mediated by the anti-
oxidant effect of aspirin in atherosclerotic vessels (142). Aspirin 
treatment also leads to a reduction in free radical stress evident by 
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decreased lipid peroxidation and significantly prevented reduction 
in glutathione content in endothelial cells of hypercholesterolemic 
animals (143). Therefore, based on animal models, anti-platelet 
therapy is expected to be beneficial to AAA patients.
Ace inhibitors
Activation of the renin–angiotensin system has been implicated 
in the genesis of several cardiovascular disorders including AAA 
(144). Angiotensin II (Ang II) is strongly upregulated in human 
aortic aneurysms, and the Ang II increase is mediated by pathways 
dependent on ACE and chymase (145). In experimental studies, 
ACE inhibitors were found to reduce AAA rate (146), and in a 
retrospective clinical study, they were associated with a reduction 
in the risk of AAA rupture (147). However, there are controversial 
data. Some studies indicated that AAA patients treated with ACE 
inhibitors, but not those treated with other anti-hypertensives, 
seemed to be less likely to present with ruptured AAA as a recent 
Canadian study showed (147). By contrast, Wilmink et al. did not 
confirm the beneficial effect of ACE inhibitors on AAA progres-
sion (148), while others found a reverse, negative effect of ACE 
inhibitors on AAA (149).
Recently, Kortekaas et al. (150) presented results where patients 
treated with the ACE inhibitor ramipril (5 mg/day, for 4 weeks) 
had significantly lower levels of NF-κB and Ang II activity in AAA 
tissue and a lower content of IL-8 and MCP-1. The effect of ACE 
inhibitors on inflammatory mediators may result in a change of 
cell activation and, for instance, a shift in macrophage signature 
toward a predominance of alternatively activated macrophages. 
This may at least in part, account for the reduced expression of 
the proteases MMP-9, cathepsin L, and S, which are all considered 
instrumental in the process of AAA growth (85). Moreover, ACE 
inhibitors influence elastolytic MMP levels in the AAA wall to 
reduce elastin degradation within the vessel (146).
conclusion
Substantial progress has been made in recent years in understand-
ing the process of AAA development and progression. The ILT 
has emerged as a major player, which “entraps” leukocytes, in 
particular neutrophils, to create a pro-oxidant and proteolytic 
environment that leads to vessel wall destabilization. The early 
processes of aneurysm development may be particularly sensitive 
to changes in the pathways controlling oxidative or nitroxida-
tive stress where localized deregulation may induce endothelial 
and SMC dysfunction and promote thrombus formation. Thus, 
pharmacological treatment options for AAA patients progres-
sively incorporate anti-oxidant, anti-inflammatory, and anti-
proteolytic drug effects in addition to cholesterol, hemostasis, 
or blood pressure control. The need for surgical repair is carefully 
evaluated based on disease progression, morphological AAA 
characteristics, and patient comorbidities to avoid unnecessary 
risks. Predictive markers such as D-dimer for AAA growth are 
required to evaluate the risk for imminent rupture and further 
improve disease control.
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